Skip to main content
The EMBO Journal logoLink to The EMBO Journal
. 2018 Jan 18;37(3):384–397. doi: 10.15252/embj.201797931

Tolloid cleavage activates latent GDF8 by priming the pro‐complex for dissociation

Viet Q Le 1,2, Roxana E Iacob 3, Yuan Tian 1,2, William McConaughy 4, Justin Jackson 4, Yang Su 1,2, Bo Zhao 1,2, John R Engen 3, Michelle Pirruccello‐Straub 4, Timothy A Springer 1,2,
PMCID: PMC5793799  PMID: 29343545

Abstract

Growth differentiation factor 8 (GDF8)/myostatin is a latent TGF‐β family member that potently inhibits skeletal muscle growth. Here, we compared the conformation and dynamics of precursor, latent, and Tolloid‐cleaved GDF8 pro‐complexes to understand structural mechanisms underlying latency and activation of GDF8. Negative stain electron microscopy (EM) of precursor and latent pro‐complexes reveals a V‐shaped conformation that is unaltered by furin cleavage and sharply contrasts with the ring‐like, cross‐armed conformation of latent TGF‐β1. Surprisingly, Tolloid‐cleaved GDF8 does not immediately dissociate, but in EM exhibits structural heterogeneity consistent with partial dissociation. Hydrogen–deuterium exchange was not affected by furin cleavage. In contrast, Tolloid cleavage, in the absence of prodomain–growth factor dissociation, increased exchange in regions that correspond in pro‐TGF‐β1 to the α1‐helix, latency lasso, and β1‐strand in the prodomain and to the β6′‐ and β7′‐strands in the growth factor. Thus, these regions are important in maintaining GDF8 latency. Our results show that Tolloid cleavage activates latent GDF8 by destabilizing specific prodomain–growth factor interfaces and primes the growth factor for release from the prodomain.

Keywords: conformational dynamics, growth factor activation, myostatin, prodomain, TGF‐β

Subject Categories: Post-translational Modifications, Proteolysis & Proteomics; Signal Transduction; Structural Biology

Introduction

Growth and differentiation factor 8 (GDF8, myostatin) is one of 33 members of the transforming growth factor‐β (TGF‐β) family, which in addition to GDFs and TGF‐βs includes activins, inhibins, and bone morphogenetic proteins (BMPs). GDF8 potently inhibits skeletal muscle development. Mutation of GDF8 in humans and multiple animal species results in a hypermuscular and low body fat phenotype (Grobet et al, 1997; McPherron & Lee, 1997; McPherron et al, 1997; Schuelke et al, 2004; Clop et al, 2006). Clinical trials with GDF8 antagonists aim to treat muscle wasting associated with muscular dystrophy, cancer cachexia, sarcopenia, trauma, diabetes, and chronic obstructive pulmonary disease (Bogdanovich et al, 2002; Smith & Lin, 2013; Cohen et al, 2014).

Like other members of the TGF‐β family, GDF8 is synthesized as a proprotein precursor consisting of a signal peptide, a large N‐terminal prodomain, and a smaller C‐terminal growth factor (GF) domain (Fig 1A). In the endoplasmic reticulum (ER), the signal peptide is removed, the GDF8 monomers dimerize, and disulfide bonds form, including one between the two GF moieties, thus yielding the inactive pro‐complex precursor (pro‐GDF8). After secretion into muscle tissue, a proprotein convertase (PC) cleaves between the prodomain and growth factor domain, to yield latent GDF8 (Anderson et al, 2008).

Figure 1. Expression and characterization of GDF8 pro‐complexes.

Figure 1

  • A
    Schematic diagram of the GDF8 proprotein shown to scale. The N‐glycan attachment site at Asn71 and the Tolloid (TLD) and proprotein convertase (PC)/furin cleavage sites are indicated above the diagram. The boundaries of the N‐terminal prodomain fragment (N‐Frag) and C‐terminal prodomain fragment (C‐Frag) generated by TLD cleavage are indicated below the diagram. SP = signal peptide.
  • B
    Coomassie blue‐stained SDS–PAGE gels under non‐reducing (left) and reducing (right) conditions of purified S2‐produced pro‐GDF8 (S2) and mammalian‐expressed pro‐GDF8 (Pro), latent GDF8 (Latent), and primed GDF8 (Primed). GF = growth factor. Expected molecular mass of the disulfide‐linked pro‐GDF8 = 81.8 kDa, pro‐GDF8 monomer = 40.9 kDa, prodomain = 28.5 kDa, TLD‐cleaved N‐terminal prodomain fragment (N‐Frag) = 9.5 kDa, TLD‐cleaved C‐terminal prodomain fragment C‐Frag = 19 kDa, growth factor (GF) dimer = 24.8 kDa, and growth (GF) monomer = 12.4 kDa.
  • C–E
    Characterization of GDF8 pro‐complexes by size‐exclusion chromatography coupled to multi‐angle light scattering (SEC‐MALS). (C) Table summarizing the calculated molecular mass of pro‐, latent, and primed GDF8 as determined by SEC‐MALS. (D) Comparison of SEC elution profiles and molecular masses of pro‐, latent, and primed GDF8. The left y‐axis indicates relative absorbance (OD280) and the right y‐axis indicates calculated molar mass (g/mol). (E) Comparison of SEC elution profiles of primed GDF8 at 1.3, 0.26, and 0.13 μM. The peak absorbance for each sample was normalized to 1. The left y‐axis indicates normalized absorbance (OD280), and the right y‐axis indicates calculated molar mass (g/mol).

Source data are available online for this figure.

Pro‐complexes of GDF8, its close relative GDF11, and TGF‐βs 1, 2, and 3 are latent as recombinant proteins (Gentry et al, 1987; Wakefield et al, 1988; Khalil, 1999; Lee & McPherron, 2001; Thies et al, 2001; Hill et al, 2002; Zimmers et al, 2002; Ge et al, 2005). After cleavage by PCs between the prodomain and GF, the prodomain and GF remain non‐covalently associated in all characterized family members to date; however, the strength of this association differs (Hinck et al, 2016). TGF‐β family GFs are typically active at pM to nM concentrations. In contrast, the GF‐prodomain dissociation constants are often higher. For example, the BMP9 GF has an EC50 for cellular activation of ~ 1 nM, but the prodomain only inhibits with an IC50 of ~100 nM and has a Kd for the GF in a similar range; therefore, at bioactive concentrations, the GF and prodomain are largely dissociated and pro‐complexes show similar activity to the isolated GF in bioassays (Mi et al, 2015). Whereas isolated pro‐complexes of most TGF‐β family members are active, the GDF8 prodomains and GF dimer remain tightly and non‐covalently associated in a latent pro‐complex that is not competent for signaling (Lee & McPherron, 2001; Thies et al, 2001; Hill et al, 2002); the prodomains block receptor binding to the GF and prevent activation of downstream signaling (Lee & McPherron, 2001).

Why some TGF‐β family members are active and others are latent as pro‐complexes is incompletely understood. The basis for latency of pro‐TGF‐β1 was illuminated by its crystal structure, which showed a ring‐like structure with the GF dimer surrounded by the prodomain dimer (Shi et al, 2011). On one side, large arm domains in each prodomain disulfide link to one another and interact with the GF near the periphery of the ring, with a solvent‐filled channel between the prodomain and GF at the center of the ring. On the other side, smaller prodomain helical and latency lasso structural elements form a straitjacket that wraps around the GF. Cysteines near the N‐terminus of the TGF‐β1 prodomain disulfide link in the ER to “milieu molecules” that store latent pro‐TGF‐β1 on cell surfaces or in the extracellular matrix for subsequent activation (Hinck et al, 2016). Other family members including GDF8 have similar cysteines that might link to milieu molecules and further stabilize latency; however, their structural and functional relevance is unclear. More recent structures of two non‐latent TGF‐β1 family members, BMP9 and activin A, reveal important differences among pro‐complexes (Mi et al, 2015; Wang et al, 2016). Both have V‐shaped or linear overall shapes, termed open‐armed, that contrast with the ring‐like, cross‐armed conformation of TGF‐β1. Further differences were revealed, particularly with BMP9, in the manner of association of straitjacket elements with the GF.

Here, we ask why GDF8 is latent, and what changes when it becomes activated. GDF8 and its close relative GDF11 are activated by BMP1/Tolloid (TLD) metalloprotease‐mediated cleavage of the prodomain between the straitjacket elements and the arm domain (Wolfman et al, 2003; Ge et al, 2005). Tolloid‐like protein 2 (TLL2), used in this paper, is among the most active on GDF8 of the four TLD proteases found in mammals (Wolfman et al, 2003). While TLD cleavage clearly activates signaling by the GF, whether the two prodomain fragments rapidly dissociate from the GF after cleavage, or remain associated with the GF in a “primed” state, is not known. Here, we compare pro‐GDF8, the state prior to PC cleavage; latent GDF8, the state after PC cleavage; and primed GDF8, a state after TLD cleavage in which we found the persistence of substantial prodomain–GF association. We use two orthogonal techniques, negative stain electron microscopy (EM), and hydrogen–deuterium exchange mass spectrometry (HDX‐MS) to compare these three states. The results provide important insights into the structure and mechanism of activation of GDF8. Our results and those of two other groups were concurrently posted to BioRxiv (preprint: https://doi.org/10.1101/153403, now published as Cotton et al, 2018; preprint: Le et al, 2017; preprint: Walker et al, 2017b). After submission, we were able to read one another's manuscripts and learn of remarkable concordance. In this MS, we refer not only to what we initially deduced based on comparisons to structures of previously published TGF‐β1 family member pro‐complexes (preprint: Le et al, 2017), but also to what we learned from concurrently submitted crystal structure and small‐angle X‐ray scattering analysis of pro‐GDF8 (Cotton et al, 2018; preprint: Walker et al, 2017b).

Results

Molecular composition of three types of GDF8 prodomain–GF complexes and their functional activity

To interrogate the effect of pro‐complex maturation by PC cleavage and activation by Tolloid cleavage, we generated three different GDF8 pro‐complexes: (i) the uncleaved GDF8 precursor pro‐complex (pro‐GDF8), (ii) furin‐cleaved GDF8 pro‐complex (latent GDF8), and (iii) furin‐ and Tolloid‐cleaved GDF8 pro‐complex (primed GDF8). Stable 293 transfectants were grown in the presence (to generate pro‐GDF8) or absence (to generate partially PC‐cleaved GDF8) of the PC inhibitor decanoyl‐Arg‐Val‐Lys‐Arg‐chloromethylketone. Pro‐GDF8 or partially PC‐cleaved material was purified from conditioned media by Ni‐NTA and size‐exclusion chromatography (SEC). To obtain latent GDF8 and primed GDF8, partially PC‐cleaved GDF8 was incubated with purified furin protease alone or with furin and TLL2‐conditioned media, respectively. FLAG‐tagged proteases were then removed on an affinity column, and pro‐complexes were purified by an additional round of SEC.

Purified pro‐GDF8 was predominantly uncleaved and migrated as a 110‐kDa disulfide‐linked precursor dimer under non‐reducing conditions and a doublet of 52‐ and 47‐kDa precursor monomers under reducing conditions (Fig 1B). Pro‐GDF8 produced in S2 insect cells, shown for comparison, migrated at 100 and 47 kDa in non‐reducing and reducing SDS–PAGE, respectively. S2 cells make high‐mannose N‐glycans. The identical migration of the insect cell material to the 47‐kDa band from mammalian 293 cells in reducing gels suggests that the 52‐ and 47‐kDa mammalian pro‐GDF8 monomers have complex and high‐mannose glycans, respectively (Anderson et al, 2008); pro‐GDF8 has a single predicted N‐linked glycan attachment site at Asn71 in the straitjacket region (Fig 1A).

Furin cleavage of pro‐GDF8 to create latent GDF8 converted the precursor dimer of 110 kDa in non‐reducing SDS–PAGE to 35‐ and 31‐kDa prodomain monomers and a 20‐kDa GF dimer (Fig 1B). Reducing SDS–PAGE of latent GDF8 showed the same 35‐ and 31‐kDa prodomain monomer bands as non‐reducing PAGE together with a 13‐kDa GF monomer.

TLL2 cleavage to obtain primed GDF8 converted the prodomain monomer bands of 35 and 31 kDa seen in latent GDF8 to bands at 19 and 15 kDa under both non‐reducing and reducing conditions (Fig 1B). Bands from reducing SDS–PAGE were subjected to Edman degradation. The N‐terminal sequence of the 15‐kDa band was HXXXXXNEN, corresponding to the N‐terminal sequence of the His‐tagged prodomain (HHHHHHNEN). The N‐terminal sequence of the 19‐kDa band was DXSXXGXLE, showing that it corresponds to the fragment C‐terminal to the TLD cleavage site (DDSSDGSLE). Additional bands corresponding to a 20‐kDa GF dimer and 13‐kDa GF monomer were seen in non‐reducing and reducing SDS–PAGE, respectively. Since the primed GDF8 had run as a symmetric peak in SEC after TLL2 cleavage, these results showed that the N‐terminal and C‐terminal prodomain fragments largely remained associated with the GF dimer, and justified terming this material primed GDF8. We further term the N‐terminal 15‐kDa and C‐terminal 19‐kDa cleaved prodomain fragments the N‐prodomain and C‐prodomain fragments, respectively. The greater diffuseness in SDS–PAGE of the N‐prodomain than C‐prodomain fragment and higher observed mass in SDS–PAGE of 15 kDa compared to the expected protein mass of 9.5 kDa of the N‐prodomain fragment correlate with its predicted N‐linked glycan attachment site. The mass from SDS–PAGE of the C‐prodomain fragment of 19 kDa agreed with its predicted protein mass of 19 kDa. The mass from SDS–PAGE of 13 kDa for the GF monomer agreed with its predicted protein mass of 12.4 kDa. Moreover, a mass of 20 kDa for the GF dimer in non‐reducing SDS–PAGE is consistent with the expectation that intra‐chain disulfide bonds in each monomer increase migration of the GF dimer in SDS–PAGE.

The molecular masses of the three classes of GDF8 pro‐complexes made in mammalian cells were characterized by SEC with multi‐angle light scattering (SEC‐MALS), which estimates the total mass of glycoproteins independently of their shape (Fig 1C–E). Samples were applied at concentrations ranging from 0.13 to 1.3 μM. Pro‐GDF8 and latent GDF8 had molecular masses of 86 and 82 kDa, respectively, consistent with their expected protein masses of 82 kDa and additional N‐glycosylation (Fig 1C and D). Furthermore, similar masses were estimated for pro‐GDF8 and latent GDF8 when they were used at differing concentrations of 1.3 and 0.26 μM (Fig 1C).

In contrast, primed GDF8 yielded a main peak with a substantially lower mass of 70–59 kDa and a secondary, later‐eluting peak. As the concentration of primed GDF8 in the experiment was reduced from 1.3 to 0.26 to 0.13 μM, the main peak in gel filtration eluted later with a decrease in estimated molecular mass (Fig 1C and E), and the amount of material in the secondary peak increased relative to the main peak (Fig 1E). These results show concentration‐dependent complex dissociation, and thus, that Tolloid cleavage primes GDF8 for dissociation. The samples had been stored frozen and diluted just prior to SEC‐MALS evaluation; therefore, dissociation of prodomain fragments from the GF dimer occurred on the timescale of sample handling and SEC‐MALS. Dissociation has first‐order kinetics, and thus, the same proportion of dissociation must have occurred at all concentrations. Therefore, the concentration dependence of the molecular mass of the main peak and the increasing proportion of the secondary peak with decreasing primed GDF8 concentration strongly suggest that at higher concentrations, dissociation was partially balanced by reassociation. These results suggest dissociation constants in the range of experimentally used concentrations. Notably, the highest concentration of primed GDF8 used in the experiments had a calculated molecular weight that was less than that of pro‐ or latent GDF8. To achieve a mass of 70 kDa, it appears that the GF dimer must be present in the complex and associate with a combined total of ~3 prodomain fragments on average. Overall, the results suggest that cleavage at the TLD site enables partial dissociation of the primed GDF8 pro‐complex in a concentration‐dependent fashion.

We compared the signaling activities of the three GDF8 pro‐complexes to one another and to commercially obtained, recombinant GDF8 using GDF8‐responsive luciferase reporter cells (Fig 2A). Because of the high signaling potency of GDF8, GDF8 complexes were diluted to much lower concentrations than in the SEC‐MALS experiments. Pro‐GDF8 had little or no activity. Latent GDF8 induced minimal signaling with an estimated EC50 of 2.62 nM, consistent with previous observations and likely reflecting the dissociation of the prodomain at such low protein concentrations (Lee & McPherron, 2001; Thies et al, 2001; Hill et al, 2002). In contrast, primed GDF8 and the purified GDF8 growth factor signaled equivalently, with EC50 values of 0.074 and 0.078 nM, respectively. The equivalent activities of primed GDF8 and the GDF8 GF showed that TLL2 cleavage completely activated latent GDF8 and resulted in a 35‐fold higher signaling potency relative to latent GDF8.

Figure 2. Signaling activity of GDF8 pro‐complexes and effect of GDF8 antagonists on primed GDF8 as measured in a cell‐based, Smad‐responsive luciferase reporter assay.

Figure 2

  1. Signaling activity of pro‐GDF8 (green), latent‐GDF8 (red), and primed GDF8 (blue) compared to mature GDF8 growth factor (black).
  2. Inhibition curves for FST‐315 (lavender), GASP‐1 (orange), and FSTL3 (teal) titrated into reporter cells treated with 1 nM mature GDF8 (solid lines) or primed GDF8 (dashed lines).
  3. IC50 values for FST‐315, GASP‐1, and FSTL3 obtained from cells treated with 1 nM mature or primed GDF8.
Data information: Plotted data represent the mean ± s.d. of triplicate measurements. EC50 and IC50 values are from non‐linear square fitting of the data to dose–response curve; errors represent the fitting errors.

The issue of the fate of the prodomain fragments following Tolloid family cleavage is biologically important, because the GDF8 prodomain not only shields it from its type I and type II signaling receptors, but also from antagonists including follistatin (FST), follistatin‐like 3 (FSTL3), and GDF‐associated serum protein‐1 (GASP‐1) that strongly negatively regulate GDF8 signaling (Hill et al, 2003; Sidis et al, 2006; Lee & Lee, 2013; Hinck et al, 2016). Thus, we tested whether the continued—albeit partial—association of the TLD‐cleaved prodomain fragments in primed GDF8 inhibits binding of FST, FSTL3, or GASP‐1 (Fig 2B and C). FST exists in three isoforms (288, 303, and 315) that reportedly bind and inhibit GDF8 at similar potencies (Sidis et al, 2006). Titrations of FST‐315, FSTL3, and GASP‐1 in reporter cells treated with 1 nM primed GDF8 yielded inhibition curves that were similar to those obtained from cells treated with 1 nM mature GDF8 (Fig 2B). FST‐315 and GASP‐1 inhibited primed and mature GDF8 equivalently with IC50 values in the range of 1.05–1.34 nM (Fig 2C). FSTL3, while slightly weaker than FST‐315 and GASP‐1, also inhibited primed and mature GDF8 comparably (IC50 of 7.90 and 7.28 nM, respectively; Fig 2C). These results indicate that TLD‐cleaved prodomain fragments in primed GDF8 do not afford protection against FST‐315, FSTL3, and GASP‐1 at the concentrations we tested.

Hydrogen–deuterium exchange mass spectrometry

We used HDX‐MS to investigate the structural differences among the three types of GDF8 pro‐complexes, and more specifically, to gain insights into the effects of PC and TLL2 cleavage on polypeptide backbone dynamics (Fig 3). For HDX‐MS, GDF8 pro‐complexes at concentrations of 11–25.4 μM were diluted 15‐fold into 99% D2O buffered at pD 7.5 and incubated for time periods varying from 10 s to 4 h to allow exchange of pro‐complex backbone amide hydrogens with solvent deuteriums. Labeling was quenched in H2O buffered at pH 2.5 with Tris (2‐carboxyethyl) phosphine (TCEP) to reduce disulfides. Samples were digested online with pepsin and subjected to liquid chromatography coupled to mass spectrometry (LC‐MS) to determine, for each peptide, the number of hydrogens substituted with deuterium. Measurements were taken in triplicate, that is, each time point was analyzed three times in an independent measurement. Overall, we obtained ~88% peptide coverage for each of the three GDF8 pro‐complexes (Fig 3A and Appendix Figs S1 and S2). Coverage of the prodomain was essentially complete; less coverage of the GF correlated with its high content of disulfide‐bonded cysteines which challenges reduction.

Figure 3. HDX‐MS of GDF8 pro‐complexes at pD 7.5.

Figure 3

  1. HDX of GDF8 pro‐complexes compared to pro‐TGF‐β1 R249A. The color (according to the scale shown) represents the percentage of deuterium incorporation for each peptide after 1 min in deuterium and is superimposed onto a structure‐based sequence alignment of TGF‐β1 R249A and GDF8. Secondary structures based on the pro‐TGF‐β1 and pro‐GDF8 crystal structure are shown above and below the sequences, respectively. PC/furin and TLD cleavage sites are indicated by arrowheads. Dot (•) marks the Cys4 residue in pro‐TGF‐β1 that disulfide links to LTBPs and GARP. Asterisks (*) mark cysteines in the GDF8 prodomain that are discussed in the text. Numbered lines below the alignment represent peptides 1–10 followed by HDX‐MS from pro‐, latent, and primed GDF8 samples that are compared in the text and in panels (B and C).
  2. Deuterium incorporation graphs for peptic peptides 1–10 from pro‐, latent, and primed GDF8. Values represent the mean of three independent measurements; error bars, s.d.
  3. Peptides that reveal enhanced HDX in primed GDF8 were mapped onto the corresponding regions in the pro‐GDF8 crystal structure (pdb: 5NTU), which include the prodomain α1‐helix, lasso helix, fastener, and β1‐strand and the growth factor β6′‐ and β7′‐strands. Prodomain monomers 1 and 2 (Pro1 and Pro2) are in cyan, and growth factor monomer 1 (GF1) is in light pink. Peptides with enhanced HDX are numbered and colored blue in Pro1 and Pro2 and magenta in GF2.

Hydrogen–deuterium exchange reports only on backbone amide hydrogens, as deuterium incorporated at other positions such as side chains reverts back to hydrogen during analysis (Wales & Engen, 2006). Backbone positions that are protected from HDX exchange include those that are buried and thus less accessible to solvent and those that are strongly hydrogen‐bonded. For comparison to GDF8 pro‐complexes, we also measured HDX of a pro‐TGF‐β1 R249A PC site mutant at pD 7.5, extending previous data at pD 8 (Dong et al, 2017). Alignment of the pro‐TGF‐β1 and GDF8 pro‐complexes enables comparison of exchange in homologous regions (Fig 3A).

Before coming to differences among the three types of GDF8 pro‐complexes, we first describe overall shared features, along with differences and similarities with pro‐TGF‐β1. Figure 3A color codes the amount of HDX of peptides after 1 min of labeling. Exchange at five time points between 10 s and 4 h is shown in Fig 3B for selected peptides and for all peptides in Appendix Figs S1 and S2. Low deuteration in both TGF‐β1 and GDF8 pro‐complexes is found in the prodomain at the C‐terminal portion of the α1‐helix, in the β1‐, β3‐, β4‐, and β10‐strands, and in the GF in the α2′‐helix and the β6′‐ and β7′‐strands, supporting overall structural similarity. In TGF‐β1, the prodomain α1‐helix and β1‐strand pack against the GF α2′‐helix and β6′‐ and β7′‐strands (Shi et al, 2011). Additionally, the prodomain β1‐strand hydrogen bonds to the GF β7′‐strand to link prodomain and GF β‐sheets into a super β‐sheet. That the α1‐helix, β1‐strand, and β6′‐ and β7′‐strands are among the slowest exchanging regions in TGF‐β1 supports their importance in maintaining prodomain–GF interactions and hence latency. Furthermore, these are among the slowest exchanging regions in GDF8, suggesting that similar interactions between prodomain and GF elements maintain latency in TGF‐β1 and GDF8 (Fig 3A and Appendix Figs S1 and S2).

The latency lasso in the TGF‐β1 prodomain loosely wraps around the GF α2′‐helix and the tip of the “finger” formed by the GF β6′‐ and β7′‐strands. The latency lasso varies among pro‐TGF‐β1 structures (Dong et al, 2017), and in agreement, shows fast exchange (Fig 3A). Contrasting results were obtained with the region of GDF8 corresponding to the C‐terminal portion of the latency lasso, which contains six more residues than in TGF‐β1 (Fig 3A and Appendix Figs S1 and S2). The GDF8 latency lasso was cleaved by pepsin into two peptides. While the N‐terminal GDF8 latency lasso‐like peptide was highly deuterated (> 60% at 1 min) like pro‐TGF‐β1, the C‐terminal peptide was much less deuterated. Thus, we concluded that the C‐terminal portion of the longer latency lasso of GDF8 must adopt a more compact, stable structure, consistent with its high content of Leu and Pro residues, and may interact with the GF and contribute to latency (preprint: Le et al, 2017). Indeed, the pro‐GDF8 crystal structure shows that this insert forms a lasso α‐helix that forms a hydrophobic interface with the GF finger tips (Fig 3C; Cotton et al, 2018).

Comparisons among the three types of GDF8 pro‐complexes reveal important similarities and differences. The HDX‐MS profiles of pro‐ and latent GDF8 are essentially identical, even in the C‐terminal peptide of the prodomain and N‐terminal peptide of the GF that flank the PC cleavage site (Fig 3A). Deuterium incorporation is superimposable from 10 s to 4 h (Appendix Figs S1 and S2), showing that PC cleavage between the pro‐ and GF domains has no effect on the non‐covalent structure or dynamics of the pro‐complex. In contrast, cleavage with TLL2 at the TLD site markedly increases deuterium exchange in regions of prodomain–GF association. The TLD cleavage site between Arg98 and Asp99 in pro‐GDF8 is disordered in its crystal structure (Cotton et al, 2018) and corresponds in TGF‐β1 to a region that follows the α2‐helix (Fig 3A and C). Two peptides that flank the TLD site, YDVQR98 and D99DSSDGSL, were recovered only in primed GDF8 (Fig 3A) and confirmed TLL2 cleavage and its correlation with enhanced HDX in regions of putative prodomain–GF interactions as described in the next paragraph. However, recovery of some peptides spanning the cleavage site in primed GDF8 (residues 90–106, 94–106, and 95–106, Appendix Fig S1) also confirmed that TLL2 cleavage was not complete.

TLD site cleavage enhanced HDX in peptides that cluster to interacting regions of the straitjacket and GF. Based on structural alignments between GDF8 and TGF‐β1, these changes in HDX correspond to the predicted α1‐helix, latency lasso, α2‐helix, fastener, and β1‐strand in the GDF8 prodomain and the β6′‐ and β7′‐strands in the GDF8 growth factor, as now confirmed by the pro‐GDF8 crystal structure (Fig 3A–C). Greater deuteration in these regions after TLL2 cleavage suggests structural destabilization with increased conformational dynamics and flexibility. Peptides with more exchange in primed GDF8 compared to pro‐GDF8 and latent GDF8 are shown in Fig 3C with darker colors than other segments of the prodomain and GF and are numbered identically in Fig 3A–C as peptides 2–7 and 10. Peptides 1, 8, and 9 in Fig 3A and B are, by comparison, peptides in the N‐ and C‐prodomain fragment and GF that show no difference in exchange among the three types of GDF8 pro‐complexes. All peptides with more HDX in primed GDF8 cluster to GF‐interacting regions of the N‐prodomain fragment (i.e., the C‐terminal portions of the α1‐helix and latency lasso), the C‐prodomain fragment (i.e., the β1‐strand and adjacent loops), and the GF (i.e. the finger). Thus, TLD site cleavage increases the structural lability of these regions. Differences in HDX among peptides in a single type of pro‐complex provide further structural insights. The deuterium incorporation graphs in Fig 3B and Appendix Figs S1 and S2 have scales in which the maximum value of the y‐axis corresponds to the maximum number of backbone amide hydrogens in each peptide that can take up deuterium. Dashed lines show 50% exchange. Peptide 2 (IKIQIL) and overlapping peptide 56–66 (Appendix Fig S1) in the C‐terminal portion of the α1‐helix are two of the slowest exchanging peptides in latent GDF8 (Fig 3B and Appendix Figs S1 and S2). These results show that the C‐terminal portion of the α1‐helix has a very important role in stabilizing GDF8 and further suggest that the increased α1‐helix dynamics observed after TLD cleavage is likely to make an important contribution to GDF8 activation.

Electron microscopy

We used EM to define the overall shape of GDF8 pro‐complexes and explore whether furin or TLL2 cleavage induced large‐scale conformational change during GDF8 pro‐complex maturation and activation. Pro‐complexes were subjected to SEC (Fig 4A) and immediately applied to EM grids at concentrations of 1–5 pM, that is, concentrations that were substantially lower than used in SEC‐MALS or HDX. Primed GDF8 eluted later than pro‐ and latent GDF8 (Fig 4A), as also shown in Fig 1D, and the main peak of primed GDF8 was followed by a broad shoulder in which the GF and C‐terminal prodomain fragment were prominent (Fig 4B). The N‐prodomain fragment was present in the main primed GDF8 peak and in fractions immediately after this peak including fraction 19, but was less prominent in the trailing portions of the shoulder. The C‐prodomain fragment was prominent in both the peak and trailing fractions. These results suggest that some degree of dissociation of primed GDF8 occurred during gel filtration. GDF8 pro‐complexes from peak fractions were electrostatically adsorbed to glow‐discharged carbon grids, stained and fixed with uranyl formate, and examined by electron microscopy, and ~5,000 particles were subjected to alignment, classification, and averaging (Appendix Fig S3).

Figure 4. Conformation of GDF8 pro‐complexes under negative stain electron microscopy (EM).

Figure 4

  • A
    Gel filtration elution profiles (S200 column) of pro‐, latent, and primed GDF8 immediately prior to negative staining.
  • B
    Coomassie blue‐stained SDS–PAGE gels of elution fractions 15–26 from gel filtration of primed GDF8 (A) under non‐reducing (top) and reducing (bottom) conditions.
  • C–G
    Representative EM class averages of pro‐GDF8 (C), latent GDF8 (D), primed GDF8 (E), pro‐TGF‐β1 (F; Shi et al, 2011), and pro‐BMP9 (G; Mi et al, 2015). Scale bars, 100 Å. Class averages of GDF8 pro‐complexes (C–E) were cross‐correlated with 2D projections of pro‐GDF8 (pdb: 5NXS) and pro‐BMP9 (pdb: 4YCG) crystal structures, whereas cross‐correlations of pro‐BMP9 class averages with the pro‐BMP9 crystal structure was previously performed in Mi et al (2015); the best‐correlating projection and its correlation coefficient are shown below each class average.
  • H–J
    Crystal structures of cross‐armed pro‐TGF‐β1 (pdb: 5FFO) (H), open‐armed pro‐BMP9 (pdb: 4YCG) (I), and V‐armed pro‐GDF8 (pdb: 5NTU) (J) superimposed on the cystine knot of the growth factor dimer. Important secondary structures involved in prodomain–GF interactions are labeled for each pro‐complex structure.
  • K–M
    Conformation of the growth factor dimer from pro‐complex crystal structures. The growth factor dimer adopts a closed conformation in pro‐TGF‐β1 (pdb: 3RJR) (K) (Shi et al, 2011) and pro‐BMP9 (pdb: 4YCG) (L) (Mi et al, 2015), and an open conformation in pro‐GDF8 (pdb: 5NTU).
  • N–P
    Crystal structures of the GDF8 growth factor in different conformations. The apo form (pdb: 5JI1) (Walker et al, 2017a) adopts an open conformation (N). In contrast, the GDF8 growth factor adopts a closed conformation when in complex with the antagonist FSL3 (O) (pdb: 3sek) (Cash et al, 2012) and yet another conformation when bound to Fab (P) (pdb: 5f3b) (Apgar et al, 2016).

Source data are available online for this figure.

Negative stain EM of pro‐ and latent GDF8 showed a V‐shaped conformation, which we term V‐armed (Fig 4C and D). This conformation contrasts with the ring‐like, cross‐armed conformation of latent pro‐TGF‐β1 (Shi et al, 2011; Fig 4F). No differences between pro‐ and latent (furin‐cleaved) GDF8 were detectable in EM, consistent with their essentially identical HDX (Fig 3 and Appendix Figs S1 and S2). We have previously termed pro‐BMP9 open‐armed based on its EM and crystal structures (Fig 4G; Mi et al, 2015) and to contrast it with cross‐armed pro‐TGF‐β1. Crystal structures show that pro‐BMP9, pro‐GDF8, and pro‐activin A may also be considered V‐armed, with a more obtuse V‐angle in pro‐BMP9 and pro‐GDF8 (Mi et al, 2015; Cotton et al, 2018; Fig 4I and J) than in pro‐activin A (Wang et al, 2016). Pro‐ and latent GDF8 class averages cross‐correlate essentially equally well with the pro‐GDF8 and pro‐BMP9 crystal structures (bottom two rows in Fig 4C and D). In contrast, pro‐ and latent GDF8 class averages do not cross‐correlate as well with the pro‐activin A crystal structure which has a more acute V‐angle (Wang et al, 2016; preprint: Le et al, 2017). SAXS also indicates that pro‐GDF8 adopts an open‐ or V‐armed conformation rather than a cross‐armed conformation, albeit with SAXS envelopes fitting better to the pro‐activin A than the pro‐BMP9 crystal structure (preprint: Walker et al, 2017b).

In EM, pro‐BMP9 appears more linear than V‐armed (Fig 4G). The pro‐BMP9 crystal structure projections that cross‐correlate best with EM class averages of pro‐GDF8 differ in orientation from those that cross‐correlate best with EM class averages of pro‐BMP9 (compare bottom rows of Fig 4C, D, and G). Thus, it appears that pro‐BMP9 and pro‐GDF8 differ in their preferred orientations on EM grids. Accordingly, the V‐angle of pro‐complexes in negative stain EM should be interpreted with caution, because it is dependent on orientation on the grid, which may differ among TGF‐β1 family members.

In contrast to pro‐ and latent GDF8, EM of primed GDF8 revealed marked heterogeneity in conformation and size (Fig 4E). Some primed GDF8 particles adopted a V‐armed conformation similar to pro‐ and latent GDF8 (Fig 4E, panels 1 and 2). A linear species resembled EM class averages of pro‐BMP9 (compare Fig 4E panel 3 with G). Class averages of progressively smaller‐sized particles in Fig 4E panels 4–6 may correspond to partially dissociated primed GDF8 containing a GF dimer and lacking one or more N‐ and C‐terminal prodomain fragments, or completely dissociated growth factor dimers or prodomain fragments. The complete class averages of the three types of pro‐complexes (Appendix Fig S3) highlight the comparative heterogeneity of primed GDF8, which was seen with three independent primed GDF8 preparations. This heterogeneity was seen despite the immediate application of the main peak from SEC of primed GDF8 to EM grids. Heterogeneity seen after cleavage at the TLD site is consistent with more rapid deuterium uptake seen with HDX‐MS, the smaller molecular mass of the main peak of primed GDF in SEC‐MALS, and the partial dissociation during SEC of primed GDF8 that was evident from the shoulder trailing the main peak.

Discussion

These studies illuminate important biochemical, functional, and structural aspects of GDF8 maturation and activation. The pro‐GDF8 precursor complex adopted a V‐armed conformation in EM. Latent GDF8 produced by furin cleavage of pro‐GDF8 adopted an essentially identical V‐armed conformation. This V‐armed conformation was distinct from the cross‐armed conformation of latent pro‐TGF‐β1. Our EM results are consistent with concurrent crystal structure and SAXS studies on GDF8 pro‐complexes (Cotton et al, 2018; preprint: Le et al, 2017; preprint: Walker et al, 2017b). As expected, the prodomain and GF dimer remain in stable non‐covalent association with one another in latent GDF8. Notably, HDX‐MS showed indistinguishable deuteration profiles, even in peptide segments adjacent to the PC cleavage site. Perhaps this should not be surprising, because segments that are susceptible to furin cleavage must be sufficiently flexible prior to cleavage to access the active site cleft in the large PC protease. Crystal structures of pro‐TGF‐β1 with and without PC cleavage and of pro‐activin A with and without cleavage at an artificial, eutopic cleavage site showed only small structural changes in the immediate vicinity of the cleavage site (Wang et al, 2016; Zhao et al, 2017), in agreement with our EM and HDX‐MS results.

Previous studies have shown that prodomain cleavage by Tolloid proteases activates GDF8 and GDF11 signaling (Wolfman et al, 2003; Ge et al, 2005); however, whether cleavage immediately released the GF from embrace by either or both of the two cleaved prodomain fragments was not examined. Here we have described, using GDF8, a class of TGF‐β family pro‐complex we term primed, in which cleavage of the prodomain does not immediately lead to GF dissociation from prodomain fragments, but primes the GF for subsequent dissociation. We found that primed GDF8 was labile; partial N‐ and C‐terminal prodomain fragment dissociation occurred on the timescale of sample handling and gel filtration in a concentration‐dependent fashion when samples were applied at concentrations of 0.13–1.3 μM and diluted during the gel filtration process to lower concentrations. Some dissociation occurred during gel filtration prior to EM of pM concentrations of primed GDF8. In contrast, at the higher final concentrations used in HDX‐MS (0.7–1.7 μM), there was no evidence for dissociation: Two or more individual peptides in the N‐terminal and C‐terminal prodomain fragments and the GF of primed GDF8 showed essentially identical HDX to peptides in pro‐ and latent GDF8 (peptides 1, 7, and 8 in Fig 3B and Appendix Figs S1 and S2).

The continued association of the TLD‐cleaved prodomain fragments has potential implications for GDF8 signaling. Although we did not observe protection from the antagonists FST‐315, FSTL3, and GASP‐1 (Fig 2B and C), the prodomain fragments may instead regulate binding of the type I and type II signaling receptors to the GDF8 GF. Work on the BMP9 pro‐complex revealed that the prodomain alters binding selectivity of the BMP9 GF for type II receptors and supported a model in which the BMP9 prodomain is displaced by stepwise binding of the type I and type II receptors (Sengle et al, 2008; Mi et al, 2015). Whether both the N‐ and C‐terminal prodomain fragments must dissociate prior to binding of the GDF8 GF to its receptors, or whether fragment dissociation is stepwise and can be coordinated with stepwise binding to receptors is an important topic for future research. Moreover, recent work on GDF11 showed that in vitro cleavage by the endoproteinase AspN generated a prodomain fragment capable of maintaining association with the GF without inhibiting GDF11 activity (Pepinsky et al, 2017). This fragment aligns in part with the α1‐ through α2‐helix region of the GDF8 prodomain (i.e., TLD‐cleaved N‐terminal fragment) and improves solubility of the GDF11 GF. Association of the N‐Frag in primed GDF8 may similarly maintain solubility of the GF until it reaches and binds to downstream signaling receptors.

We were unable to determine whether TLL2 cleavage alone resulted in a shape change in primed GDF8 compared to pro‐ and latent GDF8, because the small percentage (~11%) of class averages that resembled the V‐shaped conformation characteristic of pro‐ and latent GDF8 (Appendix Fig S3) might have corresponded to the small proportion of uncleaved, latent GDF8 present in GDF8 preparations (Fig 4B). Clearly, the affinity of the association of the GF with the prodomain, which will depend on the structural details and energetics of their association interfaces, will be more closely linked to latency than overall shape in EM. Furthermore, shape in negative stain EM is influenced by multiple factors including orientation on the substrate, as emphasized here by optimal cross‐correlation of GDF8 and BMP9 pro‐complex EM class averages with different projections of the BMP9 pro‐complex crystal structure. In short, the apparent angle of the V in EM is influenced by orientation of the plane of the V in the pro‐complex with respect to the plane of the EM grid. Another important influence on the shape in EM of TGF‐β1 family pro‐complexes is the orientation between the two GF monomers. In pro‐activin A (Wang et al, 2016) and pro‐GDF8 crystal structures (Fig 4J and M), the GF dimer has an open conformation that contrasts with the closed GF dimer conformation in pro‐complexes of TGF‐β1 (Fig 4H and K) and BMP9 (Fig 4I and L). If the GF in the pro‐activin A complex had a closed conformation, as seen in some activin GF complex structures with inhibitors and receptors, the pro‐complex would have to assume a markedly more obtuse V‐angle (Hinck et al, 2016; Wang et al, 2016). Notably, the apo GDF8 GF dimer structure adopts an open GF conformation (Fig 4N; Walker et al, 2017a) with a more acute V‐angle than in the pro‐complex (Fig 4M), whereas crystal structures of the GDF8 GF in complex with antagonists reveal a closed conformation and a complex with Fab reveals yet another conformation (Fig 4O and P; Apgar et al, 2016; Hinck et al, 2016). Our HDX results showed no changes in GDF8 GF regions that alter in conformation between the open and closed GF conformations, including the GF α3′‐helix (Hinck et al, 2016), and thus provided no evidence for a change in overall GF conformation associated with TLL2 cleavage.

Prodomain cysteine residues can have important roles in the TGF‐β family, and our HDX‐MS studies provide information about the structural context of the four cysteine residues present in the GDF8 prodomain. Distal from the GF, pro‐TGF‐β contains bowtie knot cysteines that dimerize the prodomain and may be important for the overall cross‐armed, ring‐like conformation of pro‐TGF‐β1 (Shi et al, 2011). Mutational removal of these cysteine residues activates TGF‐β1 (Brunner et al, 1989). Thus, while latent TGF‐β1 and GDF8 may share many of the interactions between their pro‐ and GF domains that confer latency, latent GDF8 appears to contain additional latency‐conferring structural features that compensate for its lack of prodomain dimerization; the lasso α‐helix may be one of these (Cotton et al, 2018). In the GDF8 prodomain, two pairs of cysteines are present in segments that align with the association region and the β2‐strand of TGF‐β1 (asterisks, Fig 3A). These pairs of cysteines are separated by the TLD cleavage site; since the N‐prodomain and C‐prodomain fragments are not disulfide linked to one another (Fig 1B), cysteines in the association region do not disulfide bond to cysteines in the β2‐strand. In pro‐TGF‐β1, the β2‐strand is an edge β‐strand in a β‐sheet and therefore is not as constrained structurally in family evolution as middle β‐strands; we earlier proposed a distinct conformation in GDF8 based on the much greater HDX of the peptide containing Cys137 and Cys138 in GDF8 than the corresponding peptide in TGF‐β1 (Fig 3A) and further proposed that Cys137 and Cys138 might disulfide bond to one another to form a vicinal disulfide bond (preprint: Le et al, 2017), which would be incompatible with β‐strand conformation (Ruggles et al, 2009). Indeed, the pro‐GDF8 structure demonstrates such a vicinal disulfide bond, that the β2‐strand is only two residues long in one monomer and not formed in the other monomer, compared to seven residues long in pro‐TGF‐β1, and that adjacent sequence that is part of the β2‐strand in TGF‐β1 is disordered in pro‐GDF8 (Cotton et al, 2018).

While we cannot rule out an intramolecular disulfide bond between Cys39 and Cys42 in the N‐prodomain fragment as observed for isolated GDF11 (Pepinsky et al, 2017), the presence of these cysteines in a region that corresponds to the association region of pro‐TGF‐β1 leads us to suggest that they disulfide link to an as yet unidentified molecule. Cys33 in the association region of pro‐TGF‐β1 becomes disulfide linked to either latent TGF‐β binding proteins (LTBPs) for storage in the extracellular matrix or to glycoprotein‐A repetitions predominant protein (GARP) for anchorage on the cell surface (Hinck et al, 2016). In the absence of such a partner, the association region in pro‐TGF‐β1 enjoys high HDX and a conformation that varies depending on the lattice environment in crystals (Dong et al, 2017). Similarly, peptides containing Cys39 and Cys42 in the putative association region of GDF8 show high amounts of exchange (Fig 3A) and are disordered in a crystal structure (Cotton et al, 2018). While GDF8 pro‐complexes can bind to both LTBP3 and perlecan, both interactions are non‐covalent (Anderson et al, 2008; Sengle et al, 2011). Thus, we propose that yet another molecule may become disulfide linked to Cys39 and Cys42. If this molecule either as a monomer or dimer could disulfide link to each prodomain monomer, it would increase the avidity of the prodomain and the N‐prodomain fragment for the GDF8 GF. A putative association region in activin A also contains a Cys residue, is disordered in crystal structures, and has been proposed to associate with an unidentified molecule (Wang et al, 2016).

Hydrogen–deuterium exchange mass spectrometry comparisons of primed GDF8 to pro‐ and latent GDF8 provided insights into the interactions between the prodomain and GF that are weakened by TLD cleavage. HDX‐MS results for regions N‐terminal of the TLD cleavage site showed cleavage‐enhanced exchange in multiple overlapping peptides in each of the α1‐helix, latency lasso, and α2‐helix. The increased HDX in the latency lasso was especially interesting, because it occurred in a region where GDF8 has an insertion of six residues and markedly more hydrophobic residues compared to TGF‐β1, and where HDX in GDF8 is far less than in TGF‐β1 (Fig 3 and Appendix Fig S3). The compact structure we suggested for the 6‐residue insert (preprint: Le et al, 2017) corresponds to the lasso α‐helix (Cotton et al, 2018). TLD cleavage also enhanced exchange of peptides in regions C‐terminal to the cleavage site that correspond to the fastener and β1‐strand. The Tyr‐Tyr dipeptide fastener sequence in TGF‐β1 is conserved as a Tyr‐His sequence in GDF8 (Fig 3A), and both interact with the C‐terminal portion of the α1‐helix to secure the straitjacket (Shi et al, 2011; Cotton et al, 2018). In TGF‐β1, the fastener resists TGF‐β1 activation by force (Dong et al, 2017).

Besides these regions of enhanced exchange, which were proximal in sequence to the cleavage site and correspond to all major elements of the straitjacket plus the β1‐strand of the arm domain, the only other peptides in primed GDF8 that showed a marked increase in exchange were two overlapping peptides that are ~300 residues C‐terminal to the cleavage site and cover the GF β6′‐ and β7′‐strands. These results provide strong evidence that straitjacket cleavage results in enhanced HDX, with increased exposure of the peptide backbone to solvent or increased dynamics of the peptide backbone, and that straitjacket backbone perturbation is transmitted to the backbones of the GF β6′‐ and β7′‐strands.

Alterations in HDX‐MS in primed GDF8 suggest that straitjacket elements including the α1‐helix, latency lasso, and α2‐helix and arm domain β1‐strand interact with one another and with the GF β6′‐ and β7′‐strands in GDF8 in a manner very similar to that revealed in the structure of pro‐TGF‐β1 (Shi et al, 2011). The pro‐GDF8 crystal structure (Cotton et al, 2018) further supports similarities in straitjacket–GF interactions between GDF8 and TGF‐β1 pro‐complexes. In these structures, the arm domain β1‐strand hydrogen bonds to the GF β7′‐strand to link arm domain and GF β‐sheets into a super β‐sheet. The straitjacket α2‐helix covers the super β‐sheet junction. The latency loop wraps around the GF β6′‐ and β7′‐strands that form two GF fingers. The straitjacket fastener links to the α1‐helix to encircle the GF fingers on the end opposite from the latency lasso (Fig 3C).

Our results provide a compelling model for the mechanism by which TLL2 cleavage primes GDF8, that is, releases GDF8 from latency. Many of the regions that are most strongly protected from exchange with solvent in the structure of latent GDF8 become available for exchange after cleavage at the TLD site. Regions that have low HDX are more structurally stable; thus, the greater rate of exchange of the GF straitjacket, arm β1‐strand, and the interacting GF β6′‐ and β7′‐strands in primed GDF8 can be directly related to structural destabilization with greater exposure to solvent, lower affinity between the prodomain and the GF, and dissociation of the prodomain fragments from the GF.

The HDX‐MS studies of GDF8 also provide insight into latency and activation of GDF11. Of the 33 members of the TGF‐β family, GDF11 is most similar in sequence to GDF8 (64% identity). In particular, sequences that correspond to the α1‐helix, latency lasso (including the 6‐residue latency helix insertion), α1‐helix, fastener, and β1‐strand in the prodomain and the β6′‐ and 7′‐strands in the GF of GDF8 are strongly conserved in GDF11 (Hinck et al, 2016). Although GF factor structures of GDF8 and 11 vary in conformation, follistatin 288‐bound structures of both are remarkably alike (RMSD = 0.66 Å; Cash et al, 2009; Apgar et al, 2016; Padyana et al, 2016; Walker et al, 2017a), suggesting that interaction with the same binding partner imposes similar structural constraints on the GDF8 and 11 GFs. These observations combined with conservation of overall domain architecture and secondary structure in the family (Shi et al, 2011; Mi et al, 2015; Hinck et al, 2016; Wang et al, 2016; Cotton et al, 2018) suggest that latent GDF11 forms similar prodomain–GF interfaces. Activation of GDF11 occurs via cleavage at a conserved TLD site in the prodomain (Ge et al, 2005). Moreover, in vitro cleavage of GDF11 has shown that an N‐terminal prodomain fragment that corresponds in part to the expected TLD‐cleaved product remains associated with the GF (Pepinsky et al, 2017). Thus, we propose that TLD cleavage similarly destabilizes conserved prodomain–GF interfaces in GDF11 and primes the pro‐complex for dissociation.

Our results are also in excellent agreement with mapping of inhibitory prodomain fragments (Jiang et al, 2004; Ohsawa et al, 2015; Takayama et al, 2015). The size of the minimum fragment found to be required for inhibition varied among the studies and may have correlated inversely with the concentration of the inhibitors that were achieved. Prodomain fragments used as inhibitors were derived either by addition of purified bacterial fusion proteins, by co‐transfection of mammalian cells with Fc fusions, or by addition of purified peptides. Using these three methods for obtaining inhibitory fragments, respectively, the minimal inhibitory fragment was found to include the entire straitjacket plus the arm domain β1‐strand (Jiang et al, 2004), half of the association region, the α1‐helix, and the latency lasso (Ohsawa et al, 2015), or a 23‐residue α1‐helix peptide (Takayama et al, 2015). The concentration required for half‐maximal inhibition by the peptide, ~10 μM, was far higher than for the intact prodomain, 1 nM (Thies et al, 2001). Nonetheless, our findings that the straitjacket α1‐helix has the slowest HDX of the entire GDF8 straitjacket and that the entire straitjacket region plus the arm domain β1‐strand show increased exchange with solvent in primed GDF8 are in excellent agreement with both the most minimal fragment and the largest fragment found in these studies, respectively.

In summary, our study has demonstrated that Tolloid cleavage does not immediately result in release of the GDF8 GF, but primes it for release from prodomain fragments. The HDX dynamics of GDF8 provide insights into pro‐complex structure and identify a cluster of interacting structural elements that are buried in the prodomain complex with the GF. Tolloid cleavage weakens these interactions and primes the GF for subsequent release from inhibitory embrace by the prodomain.

Materials and Methods

Expression and purification of proteins

Stable cell lines overexpressing N‐terminally 6x His‐tagged pro‐GDF8 (accession: O14793), a C‐terminally FLAG and 6X His‐tagged human furin construct (residues 1–595) (accession: P09958), and a C‐terminally FLAG and 6X His‐tagged full‐length human TLL2 construct (accession: Q9Y6L7) were established by stable integration of plasmids in Flp‐In T‐REX 293 cells (Life Technologies, Carlsbad, CA, USA). Cell lines were adapted to suspension growth in F17 media (Life Technologies), and proteins were expressed according to the manufacturer's instructions.

Different GDF8 pro‐complexes were prepared as follows. Pro‐GDF8 was purified from the supernatants of pro‐GDF8 transfectants cultured in the presence of 30 μM decanoyl‐Arg‐Val‐Lys‐Arg‐chloromethylketone (R&D Systems). Latent GDF8 was produced via in vitro cleavage of purified pro‐GDF8 by human furin protease, which had been purified by Ni‐NTA chromatography. Primed GDF8 was produced by in vitro cleavage of purified pro‐GDF8 utilizing conditioned media from stable TLL2‐expressing cells and purified furin protease. All in vitro cleavage reactions occurred at 30°C for 24 h, in protease cleavage buffer: 100 mM HEPES pH 7.5, 0.01% Brij‐35, 1 mM CaCl2, and 1 μM ZnCl2.

After 5 days of expression, culture supernatant was collected and cleared by centrifugation for 10 min at 450 × gravity at 4°C. Supernatant was then filtered by passing it through a 0.22‐μm pore filter. Filtered supernatant was combined with Tris, NaCl, and NiCl2 (final concentration of 50 mM Tris pH 8.0, 350 mM NaCl, and 0.5 mM NiCl2), purified by Ni‐NTA chromatography (Qiagen) in 20 mM Tris, pH 8.0, 500 mM NaCl, and 20 mM imidazole, and eluted with 20 mM Tris, pH 8.0, 500 mM NaCl, and 300 mM imidazole. The protein was further purified by Superdex 200 SEC equilibrated with 20 mM HEPES pH 7.5, 150 mM NaCl. An additional FLAG resin purification step (GenScript, proceeded according to the manufacturer's directions) was applied as needed for removal of the FLAG‐tagged proteases from the latent and primed preparations of GDF8. Peak fractions were pooled and concentrated to 1–2 mg/ml and aliquots flash‐frozen and stored at −80°C.

For insect cell expression, full‐length pro‐GDF8 N‐terminally tagged with His‐SBP was cloned into the S2‐2 vector (ExpreS2ion Biotechnologies) and stably integrated into Drosophila S2 cells. Cells were adapted to growth in serum‐free Excell 420 media. After 4 days, culture supernatant was collected, filtered, buffer exchanged to 20 mM Tris–HCl pH 7.5, 500 mM NaCl, and purified by Ni‐NTA chromatography as described above. After a Precision3C cleavage step to remove the His‐SBP tag, pro‐GDF8 was dialyzed against 20 mM Tris–HCl pH 7.5, 150 mM NaCl and subjected to another round of Ni‐NTA chromatography followed by Superdex 200 SEC equilibrated with 20 mM Tris–HCl pH 7.5, 150 mM NaCl.

Size exclusion and light scattering

Analysis of human pro‐GDF8, latent GDF8, and primed GDF8 by SEX coupled to multi‐angle light scattering was performed by the Keck Biophysics Facility at Yale University. The following protocol was provided by the Keck Biophysics Facility and adapted from (Hsiao et al, 2010). Samples were analyzed at concentrations of 1.3, 0.26, and 0.13 μM (primed only). The light scattering data were collected using a Superdex 200, 10/300, HR Size Exclusion Chromatography (SEC) column (GE Healthcare, Piscataway, NJ, USA), connected to High Performance Liquid Chromatography System (HPLC), Agilent 1200 (Agilent Technologies, Wilmington, DE, USA), equipped with an autosampler. The elution from SEC was monitored by a photodiode array (PDA) UV/VIS detector (Agilent Technologies), differential refractometer (OPTI‐Lab rEx Wyatt Corp., Santa Barbara, CA, USA), static and dynamic, multi‐angle laser light scattering (LS) detector (HELEOS II with QELS capability, Wyatt Corp., Santa Barbara, CA, USA). The SEC‐UV/LS/RI system was equilibrated in buffer (20 mM HEPES pH 7.5, 150 mM NaCl) at the flow rate of 0.5 ml/min or 1.0 ml/min. Two software packages were used for data collection and analysis: The Chemstation software (Agilent Technologies) controlled the HPLC operation and data collection from the multi‐wavelength UV/VIS detector, while the ASTRA software (Wyatt Corp., Santa Barbara, CA, USA) collected data from the refractive index detector, the light scattering detectors, and recorded the UV trace at 280 nm sent from the PDA detector. The weight average molecular masses, Mw, were determined across the entire elution profile in the intervals of 1 s from static LS measurement using ASTRA software as previously described (Folta‐Stogniew & Williams, 1999). For each set of data, the level of glycosylation was established from the “three‐detector” approach.

Reporter cell assays

For activity assays, samples of pro‐GDF8, latent GDF8, primed GDF8, and mature GDF8 growth factor (R&D systems) were incubated at different concentrations with 293T cells (40,000 cells per well) containing a stably integrated pGL4 plasmid (Promega, Madison, WI, USA) with a promoter comprising 12 repeats of the SMAD‐responsive CAGA sequence (AGCAGACA) (Thies et al, 2001). For inhibition assays, the reporter cells were treated with either mature GDF8 growth factor or primed GDF8 at 1 nM final concentration and immediately titrated with FST‐315, GASP1, or FSTL3 antagonists (R&D systems). Cells were incubated at 37°C for 6 h before detection of luciferase expression using BRIGHT‐GLO™ reagent (Promega) according to the manufacturer's instructions. EC50 and IC50 values were calculated from three technical replicates in Prism 7.01 using a variable slope four‐parameter non‐linear curve fit.

Hydrogen–deuterium exchange mass spectrometry

Hydrogen–deuterium exchange mass spectrometry experiments were performed using methods reported previously (Iacob et al, 2013). The three GDF8 pro‐complex forms were analyzed as follows: 3 μl of pro‐GDF8 (25.4 μM), latent GDF8 (11 μM), and primed GDF8 (20 μM) were individually diluted 15‐fold into 20 mM Tris, 150 mM NaCl, 99% D2O (pD 7.5) at room temperature for deuterium labeling. At time points ranging from 10 s to 240 min, an aliquot was taken and deuterium exchange was quenched by adjusting the pH to 2.5 with an equal volume of cold 150 mM potassium phosphate, 0.5 M Tris (2‐carboxyethyl) phosphine hydrochloride (TCEP‐HCl), H2O. Each sample was analyzed as previously described (Wales et al, 2008; Iacob et al, 2013). Briefly, the samples were digested online using a Poroszyme immobilized pepsin cartridge (2.1 × 30 mm, Applied Biosystems) at 15°C for 30 s and then injected into a custom Waters nanoACQUITY UPLC HDX Manager™ and analyzed on a XEVO G2 mass spectrometer (Waters Corp., USA). The average amount of back‐exchange using this experimental setup was 20–30%, based on analysis of highly deuterated peptide standards. All comparison experiments were done under identical experimental conditions such that deuterium levels were not corrected for back‐exchange and are therefore reported as relative (Wales & Engen, 2006). All experiments were performed in triplicate. The error of measuring the mass of each peptide averaged ± 0.12 Da in this experimental setup. The HDX‐MS data were processed using DynamX 3.0 (Waters Corp., USA).

Negative stain EM

Pro‐GDF8, latent GDF8, and primed GDF8 were purified by SEC using Superdex 200 HR pre‐equilibrated with 20 mM HEPES, pH 7.5, and 150 mM NaCl. The peak fraction was loaded onto glow‐discharged carbon‐coated grids, buffer was wicked off, and grids were immediately stained with 0.75% (wt/vol) uranyl formate and imaged with an FEI Tecnai T12 microscope and Gatan 4K × 4K CCD camera at 52,000× magnification (2.13 Å pixel size at specimen level) with a defocus of −1.5 μm. Well‐separated particles were interactively picked using EMAN2 (Rees et al, 2013). Class averages were calculated by multi‐reference alignment followed by K‐means clustering using SPIDER (Frank et al, 1996; Chen et al, 2010; Mi et al, 2011). Cross‐correlations were with 2D projections generated at 4° intervals from 20‐Å‐filtered pro‐GDF8 (pdb: 5NTU and 5NXS) and pro‐BMP9 (pdb: 4YCG and 4YCI) crystal structures. We show only cross‐correlations against 5NTU for pro‐GDF8 and 4YCI for pro‐BMP9 in Fig 4 because 5NXS and 4YCG yielded essentially identical results, respectively.

Author contributions

TAS, JRE, MP‐S, VQL, and REI conceived and designed the experiments. WMC, JJ, MP‐S, YT, VQL, and BZ expressed and purified the proteins. WMC, JJ, and MP‐S prepared the latent and primed GDF8 material and performed the signaling activity assays. REI, VQL, and BZ performed the HDX‐MS studies. VQL and YS conducted the negative stain electron microscopy experiments. VQL, REI, MP‐S, and TAS analyzed the data and wrote the manuscript. All authors revised and edited the manuscript. All authors read and approved the final manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Supporting information

Appendix

Review Process File

Source Data Figure 1

Source Data Figure 4

Acknowledgements

The authors would like to thank Melissa Chambers and Zongli Li for help with EM data collection, Prof. Thomas Wales for insightful discussions on data processing, and Margaret Nielsen for her assistance in designing figures. We also thank the groups of Marko Hyvönen (University of Cambridge) and Thomas Thompson (University of Cincinnati) for coordinating the submission of their related papers with us. We acknowledge a research collaboration with the Waters Corporation (JRE). This work was supported by NIH Grant R01CA210920. Y.T. was supported by a Komen postdoctoral research fellowship (Komen PDF15334161).

See also: TR Cotton et al (February 2018)

References

  1. Anderson SB, Goldberg AL, Whitman M (2008) Identification of a novel pool of extracellular pro‐myostatin in skeletal muscle. J Biol Chem 283: 7027–7035 [DOI] [PubMed] [Google Scholar]
  2. Apgar JR, Mader M, Agostinelli R, Benard S, Bialek P, Johnson M, Gao Y, Krebs M, Owens J, Parris K, St Andre M, Svenson K, Morris C, Tchistiakova L (2016) Beyond CDR‐grafting: structure‐guided humanization of framework and CDR regions of an anti‐myostatin antibody. MAbs 8: 1302–1318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bogdanovich SK, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature 420: 418–421 [DOI] [PubMed] [Google Scholar]
  4. Brunner AM, Marquardt H, Malacko AR, Lioubin MN, Purchio AF (1989) Site‐directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J Biol Chem 264: 13660–13664 [PubMed] [Google Scholar]
  5. Cash JR, Rejon CA, McPherron AC, Bernard DJ, Thompson TB (2009) The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding. EMBO J 28: 2662–2676 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cash JA, Angerman EB, Kattamuri C, Nolan K, Zhao H, Sidis Y, Keutmann HT, Thompson TB (2012) Structure of myostatin·follistatin‐like 3: N‐terminal domains of follistatin‐type molecules exhibit alternate modes of binding. J Biol Chem 6: 1043–1053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen X, Xie C, Nishida N, Li Z, Walz T, Springer TA (2010) Requirement of open headpiece conformation for activation of leukocyte integrin αXβ2 . Proc Natl Acad Sci USA 107: 14727–14732 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Clop AM, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibé B, Bouix J, Caiment F, Elsen JM, Eychenne F, Larzul C, Laville E, Meish F, Milenkovic D, Tobin J, Charlier C, Georges M (2006) A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 38: 813–818 [DOI] [PubMed] [Google Scholar]
  9. Cohen S, Nathan JA, Goldberg AL (2014) Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discovery 14: 58–74 [DOI] [PubMed] [Google Scholar]
  10. Cotton TR, Fischer G, Wang X, McCoy JC, Czepnik M, Thompson TB, Hyvonen M (2018) Structure of the human myostatin precursor and determinants of growth factor latency. EMBO J 37: 367–383 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dong X, Zhao B, Iacob RE, Zhu J, Koksal AC, Lu C, Engen JR, Springer TA (2017) Force interacts with macromolecular structure in activation of TGF‐β. Nature 542: 55–59 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Folta‐Stogniew E, Williams KR (1999) Determination of molecular masses of proteins in solution: implementation of an HPLC size exclusion chromatography and laser light scattering service in a core laboratory. J Biomol Tech 10: 51–63 [PMC free article] [PubMed] [Google Scholar]
  13. Frank J, Radermacher M, Penczek P, Zhu J, Li Y, Ladjadj M, Leith A (1996) SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol 116: 190–199 [DOI] [PubMed] [Google Scholar]
  14. Ge G, Hopkins DR, Ho WB, Greenspan DS (2005) GDF11 forms a bone morphogenetic protein 1‐activated latent complex that can modulate nerve growth factor‐induced differentiation of PC12 cells. Mol Cell Biol 25: 5846–5858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gentry LE, Webb NR, Lim GJ, Brunner AM, Ranchalis JE, Twardzik DR, Lioubin MN, Marquardt H, Purchio AF (1987) Type 1 transforming growth factor beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells. Mol Cell Biol 7: 3418–3427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Menissier F, Massabanda J, Fries R, Hanset R, Georges M (1997) A deletion in the bovine myostatin gene causes the double‐muscled phenotype in cattle. Nat Genet 17: 71–74 [DOI] [PubMed] [Google Scholar]
  17. Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM, Qiu Y (2002) The myostatin propeptide and the follistatin‐related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 277: 40735–40741 [DOI] [PubMed] [Google Scholar]
  18. Hill JJ, Qiu Y, Hewick RM, Wolfman NM (2003) Regulation of myostatin in vivo by growth and differentiation factor‐associated serum protein‐1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol 17: 1144–1154 [DOI] [PubMed] [Google Scholar]
  19. Hinck AP, Mueller TD, Springer TA (2016) Structural biology and evolution of the TGF‐β family. Cold Spring Harb Perspect Biol 8: a022103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hsiao HH, Nath A, Lin CY, Folta‐Stogniew EJ, Rhoades E, Braddock DT (2010) Quantitative characterization of the interactions among c‐myc transcriptional regulators FUSE, FBP, and FIR. Biochemistry 49: 4620–4634 [DOI] [PubMed] [Google Scholar]
  21. Iacob RE, Bou‐Assaf GM, Makowski L, Engen JR, Berkowitz SA, Houde D (2013) Investigating monoclonal antibody aggregation using a combination of H/DX‐MS and other biophysical measurements. J Pharm Sci 102: 4315–4329 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jiang MS, Liang LF, Wang S, Ratovitski T, Holmstrom J, Barker C, Stotish R (2004) Characterization and identification of the inhibitory domain of GDF‐8 propeptide. Biochem Biophys Res Commun 315: 525–531 [DOI] [PubMed] [Google Scholar]
  23. Khalil N (1999) TGF‐beta: from latent to active. Microbes Infect 1: 1255–1263 [DOI] [PubMed] [Google Scholar]
  24. Le VQ, Iacob RE, Tian Y, McConaughy W, Su Y, Zhao B, Engen JR, Pirruccello‐Straub M, Springer TA (2017) Tolloid cleavage activates latent GDF8 by priming the pro‐complex for dissociation. bioRxiv https://doi.org/10.1101/154823 [PREPRINT] [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lee SJ, McPherron AC (2001) Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98: 9306–9311 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lee YS, Lee SJ (2013) Regulation of GDF‐11 and myostatin activity by GASP‐1 and GASP‐2. Proc Natl Acad Sci USA 110: E3713–E3722 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. McPherron AC, Lawler AM, Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF‐beta superfamily member. Nature 387: 83–90 [DOI] [PubMed] [Google Scholar]
  28. McPherron AC, Lee SJ (1997) Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94: 12457–12461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Mi LZ, Lu C, Nishida N, Walz T, Springer TA (2011) Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor. Nat Struct Biol 18: 984–989 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Mi L‐Z, Brown CT, Gao Y, Tian Y, Le VQ, Walz T, Springer TA (2015) Structure of bone morphogenetic protein 9 procomplex. Proc Natl Acad Sci USA 112: 3710–3715 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ohsawa Y, Takayama K, Nishimatsu S, Okada T, Fujino M, Fukai Y, Murakami T, Hagiwara H, Itoh F, Tsuchida K, Hayashi Y, Sunada Y (2015) The inhibitory core of the myostatin prodomain: its interaction with both type I and ii membrane receptors, and potential to treat muscle atrophy. PLoS One 10: e0133713 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Padyana AK, Vaidialingam B, Hayes DB, Gupta P, Franti M, Farrow NA (2016) Crystal structure of human GDF11. Acta Crystallogr F Struct Biol Commun 72: 160–164 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Pepinsky RB, Gong BJ, Gao Y, Lehmann A, Ferrant J, Amatucci J, Sun Y, Bush M, Walz T, Pederson N, Cameron T, Wen D (2017) A prodomain fragment from the proteolytic activation of growth differentiation factor 11 (GDF11) remains associated with the mature growth factor and keeps it soluble. Biochemistry 56: 4405–4418 [DOI] [PubMed] [Google Scholar]
  34. Rees I, Langley E, Chiu W, Ludtke SJ (2013) EMEN2: an object oriented database and electronic lab notebook. Microsc Microanal 19: 1–10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ruggles EL, Deker PB, Hondal RJ (2009) Synthesis, redox properties, and conformational analysis of vicinal disulfide ring mimics. Tetrahedron 65: 1257–1267 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350: 2682–2688 [DOI] [PubMed] [Google Scholar]
  37. Sengle G, Ono RN, Lyons KM, Bachinger HP, Sakai LY (2008) A new model for growth factor activation: type II receptors compete with the prodomain for BMP‐7. J Mol Biol 381: 1025–1039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sengle G, Ono RN, Sasaki T, Sakai LY (2011) Prodomains of transforming growth factor β (TGFβ) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J Biol Chem 286: 5087–5099 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Shi M, Zhu J, Wang R, Chen X, Mi LZ, Walz T, Springer TA (2011) Latent TGF‐β structure and activation. Nature 474: 343–349 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A (2006) Biological activity of follistatin isoforms and follistatin‐like‐3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology 147: 3586–3597 [DOI] [PubMed] [Google Scholar]
  41. Smith RCL, Lin BK (2013) Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care 7: 352–360 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Takayama K, Noguchi Y, Aoki S, Takayama S, Yoshida M, Asari T, Yakushiji F, Nishimatsu S, Ohsawa Y, Itoh F, Negishi Y, Sunada Y, Hayashi Y (2015) Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition. J Med Chem 58: 1544–1549 [DOI] [PubMed] [Google Scholar]
  43. Thies RS, Chen T, Davies MV, Tomkinson KN, Pearson AA, Shakey QA, Wolfman NM (2001) GDF‐8 propeptide binds to GDF‐8 and antagonizes biological activity by inhibiting GDF‐8 receptor binding. Growth Factors 18: 251–259 [DOI] [PubMed] [Google Scholar]
  44. Wakefield LM, Smith DM, Flanders KC, Sporn MB (1988) Latent transforming growth factor‐beta from human platelets. A high molecular weight complex containing precursor sequences. J Biol Chem 263: 7646–7654 [PubMed] [Google Scholar]
  45. Wales TE, Engen JR (2006) Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom Rev 25: 158–170 [DOI] [PubMed] [Google Scholar]
  46. Wales TEF, Fadgen KE, Gerhardt GC, Engen JR (2008) High‐speed and high‐resolution UPLC separation at zero degrees celsius. Anal Chem 80: 6815–6820 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Walker RG, Czepnik M, Goebel EJ, McCoy JC, Vujic A, Cho M, Oh J, Aykul S, Walton KL, Schang G, Bernard DJ, Hinck AP, Harrison CA, Martinez‐Hackert E, Wagers AJ, Lee RT, Thompson TB (2017a) Structural basis for potency differences between GDF8 and GDF11. BMC Biol 15: 19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Walker RG, McCoy JC, Czepnik M, Mills MJ, Hagg A, Walton KL, Cotton T, Hyvonen M, Lee RT, Gregorevic P, Harrison CA, Thompson T (2017b) Molecular characterization of latent GDF8 reveals mechanisms of activation. bioRxiv https://doi.org/10.1101/155614 [PREPRINT] [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Wang X, Fischer G, Hyvönen M (2016) Structure and activation of pro‐activin A. Nat Commun 7: 12052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, Lee SJ (2003) Activation of latent myostatin by the BMP‐1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 100: 15842–15846 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Zhao B, Xu S, Dong X, Lu C, Springer TA (2017) Prodomain‐growth factor swapping in the structure of pro‐TGF‐β1. J Biol Chem https://doi.org/10.1074/jbc.M117.809657 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ (2002) Induction of cachexia in mice by systemically administered myostatin. Science 296: 1486–1488 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Appendix

Review Process File

Source Data Figure 1

Source Data Figure 4


Articles from The EMBO Journal are provided here courtesy of Nature Publishing Group

RESOURCES